Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Child developmental issues news

Show

From To
South Africa urgently needs an antiretroviral pregnancy registry

With the dolutegravir roll-out around the corner, the time is now ripe for patients and activists to demand a prospective pregnancy registry for the whole of South Africa. Whether it is a new endeavour or piggy-backs on international efforts is a matter for debate, but it is the only way we can answer the question of dolutegravir’s safety with the minimum number of women being exposed to the drug. It’s the least that patients deserve.

Published
29 January 2019
From
Spotlight
Top 10 HIV Clinical Developments of 2018

It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

Published
20 December 2018
From
The Body Pro
Babies born to mums with HIV face higher risks even though they’re HIV negative

HIV-uninfected children born to mothers with HIV are prone to infections that are more severe, are at almost two times greater risk of dying before their first birthday, and are more likely to be born prematurely than children born to mothers without HIV.

Published
29 November 2018
From
The Conversation
Dolutegravir Use During Pregnancy: What Are the Risks?

Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

Published
22 October 2018
From
Infectious Disease Advisor
Efavirenz in HIV-positive pregnant women, risk of neurological condition in children

Researchers found children of women whose ART regimen included efavirenz were 60 percent more likely to develop a neurological condition, such as microcephaly (small head), seizures (from a high fever or other cause) and eye abnormalities than children whose mothers took other ART medications.

Published
05 October 2018
From
IDSA press release
Why the world may force women to choose: No birth control, no ARVs

A new drug could save 25 000 women living with HIV but could it come at the cost of their babies lives?

Published
22 August 2018
From
Bhekisisa
Dolutegravir preconception signal: time is up for shoddy surveillance

The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.

Published
16 July 2018
From
HIV i-Base
Dolutegravir: need to consider all pros and cons before switching in pregnancy

A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

Published
11 July 2018
From
HIV i-Base
Children born with HIV on treatment experience next-to-no developmental set-backs at the age of 5

New data on the impact of different treatment strategies on the neuro-development of young children living with HIV has been released, showing normal development in all areas apart from visual perception.

Published
25 May 2018
From
AVERT
BHIVA statement on Potential Safety Signal in Infants Born to Women Conceiving on Dolutegravir

The BHIVA HIV in Pregnancy Guidelines Writing group makes the following recommendations: all women wishing to conceive should be started on folic acid 5mg OD regardless of their cART regimen; all women commencing DTG should have a negative pregnancy test prior to initiation and ongoing method of contraception documented; we advise a review of all patient records of women aged up to 50yo on DTG with regards to conception plans, documented method of contraception and current pregnancy status; we recommend that women at risk of pregnancy be contacted by their clinic to discuss the DTG safety report, which should be clearly documented, and the woman seen in person if pregnant.

Published
23 May 2018
From
British HIV Association
← First12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.